SCHEMBL5137569

SCHEMBL5137569

CCCCn1c(CN(Cc2ccc(O)c(C(=O)OC)c2)CC2CCCCC2)cnc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
AVPR1B P47901 1/20 0.33
HDAC1 Q13547 1/20 0.33
RORC P51449 1/20 0.33
BCHE P06276 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
C5AR1 P21730 1/20 0.33
ACHE P22303 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136714 0.92 KAT8 (0.36) AGTR1FNTAFNTBAVPR1BHDAC1
SCHEMBL5134721 0.92 SMN1; SMN2 (0.39) AGTR1FNTAFNTBALDH1A1SMN1; SMN2
SCHEMBL5212722 0.88 AGTR1 (0.43) AGTR1ALDH1A1KDM4EHDAC1RORC
SCHEMBL5135282 0.88 ALDH1A1 (0.37) AGTR1ALDH1A1KDM4ENPSR1SMN1; SMN2
SCHEMBL5137530 0.88 ALDH1A1 (0.38) AGTR1ALDH1A1KDM4ENPSR1SMN1; SMN2
SCHEMBL5212718 0.85 AGTR1 (0.38) AGTR1FNTAFNTBAVPR1BRORC
SCHEMBL5136034 0.84 CXCR3 (0.36)
SCHEMBL5182726 0.84 SIRT2 (0.37) ALDH1A1SMN1; SMN2AVPR1BBCHETDP1
SCHEMBL5134947 0.82 TSHR (0.37) AGTR1ALDH1A1KDM4ERORCBCHE
SCHEMBL5182730 0.82 TDP1 (0.36) ALDH1A1KDM4ENPSR1SMN1; SMN2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed